Clinical Trial Update: Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study [Phase 1]

View source ↗

Summary

Phase 1 pilot study evaluating whether tolvaptan can reduce urinary supersaturation in nephrolithiasis due to calcium oxalate or calcium phosphate stones; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Calcium Oxalate Nephrolithiasis
• Calcium Phosphate Nephrolithiasis
• Nephrolithiasis

Drugs mentioned

• Samsca (tolvaptan) (tolvaptan)

Snippet

Sponsor: Mayo Clinic | Conditions: Nephrolithiasis, Calcium Oxalate, Nephrolithiasis, Calcium Phosphate | Phase 1 | Status: COMPLETED